RCUS Stock Price | Analyst Target 35.33 & Moderate Buy Consensus

Arcus Biosciences Inc RCUS

‎$‎19.02-0.08(-0.42%)(1D)

• Delayed prices by NASDAQ • in USD

Analyst Forecast

Consensus

Moderate Buy

Price Target

35.33

Based on analysts who covered RCUS

Invest in Arcus Biosciences Inc

Today

Invest in RCUS

Arcus Biosciences Inc News

RCUS Maintained by Citigroup -- Price Target Raised to $50.00
GuruFocus • 21.10.26 • 20:32

Arcus Biosciences (RCUS) Shares Rise on Promising Kidney Cancer Data from ARC-20 Study
GuruFocus • 20.10.26 • 18:57

Mizuho Optimistic on Arcus Biosciences (RCUS) After Casdatifan Data Boost
GuruFocus • 20.10.26 • 16:26

RCUS Stock Price Chart

The Arcus Biosciences Inc share price is on the decline this week.

The Arcus Biosciences Inc share price today is ‎$‎19.02, reflecting a ‎-0.42‎% change over the last 24 hours and ‎-15.54‎% over the past week.
The current market capitalization of RCUS is ‎$‎2.43B with an average volume in the last three months of 1.54M.
The stock has a P/E ratio of -4.89 and a dividend yield of 0%. With the stock’s beta sitting at 1.6.

RCUS Key Metrics

What Is Arcus Biosciences Inc?

Arcus Biosciences, Inc. is an American pharmaceutical company dedicated to creating cancer therapies. Its operations include the discovery, development, and commercialization of new treatments for oncology patients.
Arcus Biosciences operates in the pharmaceutical industry, specifically focusing on oncology therapeutics. The company has developed multiple prescription medicines aimed at cancer treatment, both standalone and in combination with other drugs. While an individual entity, Arcus has initiated key collaborations with other leaders in the pharmaceutical industry to further its pharmaceutical developments.

CEO: Terry J. Rosen, PhD
Employees: 601
Founded: 2015
HQ: Hayward, California, US

FAQ